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A Systematic Review and Meta-Analysis of Strength Training
in Individuals With Multiple Sclerosis Or Parkinson Disease
Travis M. Cruickshank, BSc, Alvaro R. Reyes, MSc, and Melanie R. Ziman, PhD
Abstract: Strength training has, in recent years, been shown to be
beneficial for people with Parkinson disease and multiple sclerosis.
Consensus regarding its utility for these disorders nevertheless remains
contentious among healthcare professionals. Greater clarity is required,
especially in regards to the type and magnitude of effects as well as the
response differences to strength training between individuals with
Parkinson disease or multiple sclerosis.
This study examines the effects, magnitude of those effects, and
response differences to strength training between patients with Parkin-
son disease or multiple sclerosis.
A comprehensive search of electronic databases including Phy-
siotherapy Evidence Database scale, PubMed, EMBASE, Cochrane
Central Register of Controlled Trials, and CINAHL was conducted
from inception to July 2014.
English articles investigating the effect of strength training for
individuals with neurodegenerative disorders were selected. Strength
training trials that met the inclusion criteria were found for individuals
with Parkinson disease or multiple sclerosis.
Individualswith Parkinson disease ormultiple sclerosiswere included
in the study. Strength training interventions included traditional (free
weights/machine exercises) and nontraditional programs (eccentric
cycling).
Included articles were critically appraised using the Physiotherapy
Evidence Database scale.
Of the 507 articles retrieved, only 20 articles met the inclusion
criteria. Of these, 14 were randomized and 6 were nonrandomized
controlled articles in Parkinson disease or multiple sclerosis. Six random-
ized and 2 nonrandomized controlled articles originated from 3 trials and
were subsequently pooled for systematic analysis. Strength training was
found to significantly improve muscle strength in people with Parkinson
disease (15%–83.2%) and multiple sclerosis (4.5%–36%). Significant
improvements in mobility (11.4%) and disease progression were also
reported in people with Parkinson disease after strength training.
Furthermore, significant improvements in fatigue (8.2%), functional
capacity (21.5%), quality of life (8.3%), power (17.6%), and electro-
myography activity (24.4%) were found in individuals with multiple
sclerosis after strength training.
The limitations of the study were the heterogeneity of interventions
and study outcomes in Parkinson disease and multiple sclerosis trials.
Strength training is useful for increasing muscle strength in Parkinson
disease and to a lesser extent multiple sclerosis.
(Medicine 94(4):e411)
Abbreviations: 1RM = one repetition maximum, NR = not
reported, MVIC = maximum voluntary isometric contraction,
PEDro scale = Physiotherapy Evidence Database scale.
INTRODUCTION
N eurodegenerative disorders such as Parkinson disease andmultiple sclerosis represent a major medical concern for
health professionals and national healthcare bodies.1 Both
disorders result from progressive neuronal dysfunction and
neuronal cell death leading to progressive disability and event-
ual death.2 Classical signs and symptoms customary to both
disorders include motor problems, cognitive impairment, beha-
vioral disturbances, and systemic abnormalities.3–5
There is no cure and few cost-effective drug agents for
treating people with Parkinson disease or multiple sclerosis.6,7
Recent advances in understanding the pathogenic mechanisms
responsible for each disorder may aid in the identification and
development of cost-effective disease-modifying agents in the
future.8 However, cost-effective treatments, with disease-mod-
ifying properties and symptomatic benefits are required in the
short term.
Accumulating evidence suggests that strength training is a
useful therapy for addressing many of the clinical features that
present in individuals with neurodegenerative disorders.9–11 By
definition, strength training refers to an intervention in which
participants train a muscle or group of muscles against an
external resistance.12 Whereas evidence suggests that lower
limb strength training (ie, leg press, knee extension, and knee
flexion) is beneficial for individuals with Parkinson disease and
multiple sclerosis,13–19 consensus regarding the effects, mag-
nitude of those effects, and disease-dependent responses remain
contentious. By contrast, the therapeutic utility of strength
training is well recognized in the elderly,20 individuals with
mild cognitive impairment and in those that have suffered a
stroke. Health benefits associated with strength training in
elderly individuals include improvements in strength,21,22
cardiorespiratory capacity,23 functional capacity,23,24 muscle
activity,25 body composition,26 mood,27 cognition,28,29 health-
related quality of life,30 and enhanced hemodynamic activity on
functional magnetic resonance imaging tasks.31 In individuals
who have suffered a stroke, strength training has been found
to improve muscular strength, upper and lower limb function
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and performance on functional tasks.32–34 Improvements in
selective attention, conflict resolution, associative memory,
and regional patterns of functional brain activity have also
been observed after strength training in seniors with mild
cognitive impairment.31
In the last 2 years, 3 systematic reviews have evaluated the
effects of strength training in either Parkinson disease or
multiple sclerosis.9,35,36 Findings from these reviews suggest
that strength training is useful for improving muscle strength
and some measures of functional capacity in these disorders.
Since the publication of these reviews, a number of randomized
controlled trials have been published,9,35,36 somewhat limiting
the informative capacity of previous reviews. Previous systema-
tic reviews have also included trials with confounding supple-
mentary interventions (ie, creatine monohydrate and balance
training)35,36 as well as trials without a disease control or
comparison group.9,36 These methodological limitations may
have led to an inaccurate appraisal of the effects of strength
training as a therapy in individuals with Parkinson disease or
multiple sclerosis. It is of vital importance that systematic
reviews accurately evaluate experimental therapies like strength
training because such documents inform health professionals.
In this systematic review, we provide the most recent
evidence to support a robust evaluation of the effect of strength
training in people with Parkinson disease or multiple sclerosis.
Unlike previous reviews, our study evaluates the effect of
strength training alone, in people with Parkinson disease or
multiple sclerosis. In addition, our study only selects trials that
included individuals with multiple sclerosis or Parkinson dis-
ease in the control or comparison group. Moreover, our study
evaluates through a meta-analysis, the magnitude of strength
improvements in individuals with multiple sclerosis or Parkin-
son disease in response to strength training. Finally, unlike
previous reviews, our study explores whether differences in
response to strength training exist between individuals with
multiple sclerosis or Parkinson disease.
MATERIAL AND METHODS
Search Strategy
A comprehensive search of electronic databases was con-
ducted from inception to July 2014. Electronic searches were
performed using Physiotherapy Evidence Database (PEDro)
scale, PubMed, EMBASE, Cochrane Central Register of Con-
trolled Trials, and CINAHL databases. The search strategy
utilized a population, intervention, comparison, and outcome
approach.37 The population key words were ‘‘Parkinson dis-
ease,’’ ‘‘multiple sclerosis,’’ Alzheimer disease, amyotrophic
lateral sclerosis, Huntington disease, and spinocerebellar ataxia;
the intervention key words were ‘‘strength training,’’ ‘‘progress-
ive strength training,’’ ‘‘resistance training,’’ ‘‘weight training,’’
and ‘‘strengthening programs’’; and the outcome key words
included ‘‘strength,’’ ‘‘disease severity,’’ ‘‘gait,’’ ‘‘balance,’’
‘‘fatigue,’’ ‘‘functional capacity,’’ ‘‘mood,’’ and ‘‘quality of
life’’. This initial search only found trials on strength training
in individuals with Parkinson disease or multiple sclerosis.
As this was a literature review and did not involve the
recruitment and assessment of patients, ethical approval was
not necessary.
Eligibility Criteria
Randomized controlled trials and nonrandomized con-
trolled trials that examined the effect of strength training in
individuals suffering with multiple sclerosis or Parkinson dis-
ease were included in the review. Strength training was defined
as an intervention in which participants exercised a muscle or
group of muscles against an external resistance.12 Eligible
studies included those examining the effect of strength training
in individuals with multiple sclerosis and Parkinson disease.
Exclusion criteria were as follows: case studies; observational
studies; studies with healthy controls or healthy comparison
groups; and studies employing supplementary intervention
therapies in addition to or different from strength training.
Data Extraction
Two independent authors (T.M.C. and A.R.R) extracted
data from the included studies. A specialized extraction form
was designed and recorded the following methodological
details for each study as described below.
Publication details: authors and year of publication; details
of the study: study design and number of participants, exper-
imental and control interventions, and reported outcomes (con-
trols and experimental); participant characteristics: disease
population, disease status, and age; specific intervention details:
intervention groups, mode of strength training, targeted ana-
tomical regions, setting in which the study was conducted, level
of supervision, duration of the intervention (weeks), frequency
of strength training, specific exercises employed, exercise
intensity, number of sets and repetitions performed for each
exercise, rest taken between sets and exercises, and the pro-
gression method used for strength training interventions; mod-
erator variables: participant retention and dropouts, participant
adherence, and adverse effects associated with strength training.
Corresponding authors of studies were contacted as
necessary for supplementary information not detailed in the
publication. In cases wherein authors did not respond or did not
provide supplementary methodological information pertaining
to their publication, a not reported statement was assigned.
Quality Assessment
All articles that satisfied the predefined inclusion criteria
were independently rated for quality by 2 reviewers (T.C. and
A.R.) using the PEDro scale.38 The PEDro scale is an 11 points
scale designed to examine the methodological quality of inter-
vention studies. The scale evaluates the following methodo-
logical aspects: specific eligibility criteria, randomization
allocation, concealed allocation, baseline demographic sim-
ilarities, participant blinding, therapist blinding, outcome asses-
sor blinding, whether more than 85% of participants completed
follow-up for at least 1 primary outcome, intention to treat
analysis, between group statistical comparisons, and point
estimates and variability for at least one of the primary outcome
measures. When rating each study, only criteria 2 and 11 are
considered for the PEDro scale. Initial discrepancies between
the independent authors were resolved by consensus. In
instances wherein discrepancies could not be resolved, a final
decision was made by another independent author (M.Z.).
Data Analysis and Synthesis
For analysis, studies were categorized according to disease.
The heterogeneity of populations and extensive variety of
reported outcomes prevented a meta-analysis for all outcomes,
with the exception of strength. Whereas 15 articles reported on
strength as an outcome,13–16,18,19,39–45 3 articles by Dalgas
et al16,18,19 and 2 articles byDibble et al42,43 appeared to originate
from the same trial. Strength data from 3 articles by Dalgas
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et al16,18,19 were pooled together into a single effect size for a
better interpretation of the effects of strength training on strength
as an outcome. Standardized effect sizes were calculated for the
meta-analysis using pre- and poststrength mean values for each
group (intervention and comparison) (Hedges and Olkin, 1985).
Effect sizes were corrected for the magnitude of sample size of
each study as suggested by Hedges and Olkin (1985). The risk of
publication bias in trials was examined statistically using the
egger regression test, with a significant publication bias con-
sidered to be P 0.10. All statistical analyses were performed
using STATA 9.1 (StataCorp LC, Texas, USA).
RESULTS
Articles Included
The database search strategy and results are presented in
Figure 1. Five hundred seven articles were identified by the
initial search strategy. Four hundred seventy one of the ident-
ified articles were excluded based on their title. The abstracts of
the remaining 36 articles were evaluated and 6 articles were
excluded (Figure 1). Full texts of the remaining 30 articles were
retrieved and reviewed, resulting in the exclusion of 10 articles
(Figure 1). Of the 20 articles included in the systematic review,
8 appeared to originate from 3 separate trials. Subsequently, the
extracted and reviewed data is representative of 15 independent
trials.
Methodological Quality
The methodological quality of included trials varied con-
siderably in both Parkinson disease and multiple sclerosis
populations. PEDro scores ranged from 4 to 8 points in both
Parkinson disease13,14,40,42–44,46–49 and multiple sclerosis
trials15–19,39,41,45,50,51 (Table 1).
Participants Characteristics
The number of trials included was 8 in Parkinson
disease13,14,40,42–44,46–49 and 7 in multiple sclerosis.15–19,39,
41,45,50,51 Disease population, study design, number of partici-
pants, stage of disease, mean age and standard deviation, trial
intervention, and trial outcomes are shown in Tables 2 and 3.
Intervention Characteristics
Of the 8 trials conducted in individuals with Parkin-
son disease13,14,40,42–44,46–49 (5 randomized controlled
trials13,44,46–49 and 3 nonrandomized controlled trials14,40,42,43),
5 used lower body strength training interventions,13,14,42,43,47,49
2 used a full-body strength training intervention,44,46,48 and 1
used a lower body and core strength training intervention40
(Tables 2 and 3). Training protocols ranged from 2 to 24 months
of twice to thrice weekly training.13,14,40,42–44,46–49 Only 2
trials conducted in individuals with Parkinson disease reported
on the level of supervision for strength training interven-
tions.44,46,48
Of the 7 trials conducted in multiple sclerosis15–19,
39,41,45,50,51 (5 randomized controlled trials15–19,41,45,50 and 2
nonrandomized controlled trials39,51), 5 trials trained the lower
body15–19,41,45,50 and 2 trials trained the full body39,51 (Tables 2
and 3). Intervention protocols utilized in multiple sclerosis trials
ranged from 3 weeks to 6 months of 2 to 5 times weekly
training.15–19,39,41,45,50,51 Of the 7 trials conducted in individ-
uals with multiple sclerosis, only 3 trials reported on the level of
supervision for strength training interventions.15–19,50
Risk of Bias
Statistical examination using the egger regression test
revealed no publication bias (P¼ 0.131).
Intensity and Progression of Strength Training
Two randomized44,46,47 and 2 nonrandomized controlled
trials40,42,43 conducted in Parkinson disease reported on the
intensity of strength training performed throughout the inter-
vention, whereas 3 randomized controlled trials41,45,50 reported
on the intensity of strength training in multiple sclerosis. The
progression of strength training was reported by 3 random-
ized44,46,47,49 and 3 nonrandomized controlled trials14,40,42,43 in
Parkinson disease. In contrast, there were no trials that reported
on the progression of strength training in multiple sclerosis.
Participant Retention, Adherence, and Adverse
Events
Participant retention ranged from 75% to 100% in Parkin-
son disease trials13,14,40,42–44,46–49 and from 73.3% to 100% in
multiple sclerosis trials15–19,39,41,45,50,51 (Table 4). Four trials
in multiple sclerosis ([Medina-Perez et al45 strength
training group 95.4%; control group not reported], [Dodd
et al15 strength training group 92%; control group 62%],
[Broekmans et al50 99% all groups] and [DeBolt et al51
strength training group 95%]), and 1 trial in Parkinson
disease reported on participant adherence (Paul et al47 strength
training group 84.1%; control group 94.1%) (Table 4). Five
trials in Parkinson disease13,40,44,46–48 and 6 trials in multiple
sclerosis15–19, 39,41,45,50 reported on adverse events,13,40,44,46–48
with only minor or clinically unrelated medical issues reported
(Table 4).
Outcomes Measures
Strength As an Outcome Measure in Parkinson
Disease
Three randomized controlled trials evaluated the effect of
strength training on strength in people with Parkinson dis-
ease.13,44,47 Strength was evaluated across trials using 1 repeti-
tion maximum (1RM) and maximum voluntary isometric
contraction (MVIC) protocols with torque transducers, pneu-
matic resistance machines, and dynamometers. Corcos et al44
found a significant improvement in elbow flexor muscle
strength (1RM, 15%) in the strength training group, while
off medication, after 24 months of upper and lower body
resistance training. No significant differences in strength were
found for the control group in this trial. Shulman et al13 in
another trial found a significant improvement in leg press and
leg extension strength (1RM, 16%) in individuals within the
strength training group, but not in the high or low intensity
treadmill training groups, after 3 months of thrice weekly
resistance training. Paul et al47 also reported a significant
improvement in lower limb strength (1RM, leg extension,
14.6%; knee flexion, 18.6%; hip flexion, 39.8%; hip abduction,
33.9%) and power (leg extension, 17.3%; knee flexion, 20.6%;
hip flexion, 46.3%; hip abduction, 43.1%) in the strength
training group in comparison to the sham comparison group
after 12 weeks of lower body resistance training.
Three nonrandomized controlled trials also evaluated the
effect of strength training on strength and found significant
improvements.14,40,42,43 Hass et al,40 after 10 weeks of twice
weekly lower body strength training, found a significant
improvement in knee extension (1RM, 76%) and knee flexion
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507 Potential Articles Identified From Initial Database
Searches
36 Article Abstracts Retrieved For Evaluation
6 Articles Excluded
1 Not Comparable Outcomes
4 Not Resistance Weight Bearing
1 Home based & Not Weight Bearing
30 Full Text Articles Retrieved For Evaluation
10 Articles Excluded
8 Did Not Possess A Valid
Comparison Group
2 Qualitative Studies
20 Articles Systematically Evaluated
8 Articles Excluded For Meta-analysis
5 Did Not Examine Strength
3 Articles originated from the same
trial
12 Articles Examining Strength Included In The Meta-
Analysis
471 Articles Excluded Based On Title
94 Duplicated Articles
352 Articles Not Relevant
14 Review Articles
5 Not Resistance Weight Bearing
6 Additional Complementary Therapy
•
•
•
•
•
•
•
•
•
•
•
•
FIGURE 1. Flowchart for selection of trials included in the systematic review and meta-analysis.
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(1RM, 57%) strength in the intervention group, but not in the
control group. Schilling et al14 in another trial reported a
significant improvement in leg press strength (1RM, 22%) in
the intervention group, whereas the control group showed no
significant differences. Dibble et al42,43 similarly reported a
significant improvement in quadriceps muscle strength (MVIC)
in the more (average torque 23%; peak torque 18%) and less-
affected leg (average torque 16%; peak torque 83.2%) in the
strength training intervention group only.
Strength As an Outcome in Multiple Sclerosis
Five randomized controlled trials reported on strength as
an outcome after strength training,15,16,18,19,41,45,50 with all
5 trials reporting significant improvements in strength. Strength
was evaluated across trials using MVIC, maximum voluntary
dynamic contraction, and 1RM strength protocols with pneu-
matic resistance machines, dynamometers and the Leg Extensor
Power Rig. Medina-Perez et al45 reported a significant improve-
ment in knee extension strength (MVIC, 7.7%) and power (40%
MVIC, 15.6%) in the intervention group, but not in the control
group after 12 weeks of strength training. Significant improve-
ments in leg press strength (1RM, 15%) in the intervention
group, but not the control group were also reported by Dodd
et al15 after strength training. Broekmans et al50 in line with
Medina-Perez et al,45 reported significant improvements in
isometric strength in the knee flexors and extensors (MVIC,
average knee extension 458 change: 10.8, average knee exten-
sion 908 change: 10, average knee flexor 458 change: 4, average
knee flexion 908 change: 2.3) in the intervention group as a
result of strength training. In another trial, Dalgas et al16,18,19
reported significant improvements in isokinetic, isometric, and
angular impulse knee extensor and flexor strength in the inter-
vention group ([Dalgas et al,19 MVIC at 708 knee flexion; knee
extension: 13.2%, knee flexion: 13.8%], [Dalgas et al18; maxi-
mum voluntary dynamic contraction, knee extension 908: 4.5%;
knee extension 1808:10.2%; knee flexion 908: 21.3%; knee
flexion 1808: 18.6%], [Dalgas et al,16 MVIC, knee extension:
15.7%, knee flexion: 21.3%]), but not in the control group as a
result of resistance training. Dalgas et al16 additionally reported
a significant improvement in leg press strength. Fimland et al41
in another trial reported a significant improvement in plantar
flexion strength (MVIC, 36%) in the strength training inter-
vention group, but not in the control group. In a nonrandomized
controlled trial, DeBolt et al51 reported a significant improve-
ment in leg extensor power (24%) in the intervention group,
whereas the disease control group showed no changes after
strength training.
In addition to muscle strength, significant study-specific
improvements in gait, clinical disease progression, functional
capacity, quality of life, oxidative biomarkers, mood, fatigue,
falls, skeletal muscle volume, and electromyography activity
were observed after strength training in individuals with
multiple sclerosis or Parkinson disease.13–19,39–51
Parkinson Disease Measures
Unified Parkinson Disease Rating Scale Version 3
Three randomized13,44,48 and 1 nonrandomized controlled
trial42 conducted in Parkinson disease evaluated the effect of
strength training on clinical disease progression using the
Unified Parkinson Disease Rating Scale Version 3. Corcos
et al44 reported a significant improvement on the Unified
Parkinson Disease Rating Scale Version 3 in the intervention
group (7.4 point decrease), but not in the control group after
24 months of strength training. Shulman et al13 in another study
similarly reported a significant improvement on the motor
subscale of the Unified Parkinson Disease Rating Scale Version
3 in the strength training group. Furthermore, Sage et al48 found
a significant improvement on the Unified Parkinson Disease
Rating Scale Version 3 in the strength training group. Dibble
et al42 by contrast found no improvement on the Unified
Parkinson Disease Rating Scale Version 3 in the intervention
group after strength training.
Functional Mobility
Three randomized13,46,47 and 3 nonrandomized controlled
trials14,40,42,43 evaluated the effect of strength training on
mobility in individuals with Parkinson disease. Mobility was
assessed across trials using the 10 meter timed walk test,
6 minute walk test, 50 feet walk test and timed up and go.
TABLE 1. Trial Inclusions Rated According to the Physiotherapy Evidence Database Scale
Trials
PEDro Criteria
Total ScoreNo. 1 No. 2 No. 3 No. 4 No. 5 No. 6 No. 7 No. 8 No. 9 No. 10 No. 11
Parkinson disease
RCT Paul et al47 Yes Yes Yes Yes Yes No Yes No Yes Yes Yes 8/10
PRET-PD RCT (Corcos et al44
and Prodoehl et al46)
Yes Yes Yes Yes No No Yes Yes No Yes Yes 7/10
Shulman et al13 Yes Yes No Yes Yes Yes No No No Yes Yes 6/10
Sage et al48 Yes Yes No Yes No No No Yes Yes Yes Yes 7/10
Bloomer et al49 Yes Yes No Yes No No No No No Yes Yes 4/10
Non-RCT Hass et al40 Yes Yes No Yes No No No Yes Yes Yes Yes 6/10
Schilling et al14 Yes Yes No Yes No No No No Yes No Yes 4/10
Dibble et al42,43 Yes No No Yes No No No Yes Yes Yes Yes 6/10
Multiple Sclerosis
RCT Medina-Perez et al45 Yes Yes No Yes No No No Yes Yes Yes Yes 6/10
Dalgas et al16–19 Yes Yes Yes Yes No No Yes No Yes Yes Yes 6/10
Dodd et al15 Yes Yes Yes Yes No No Yes Yes Yes Yes Yes 8/10
Broekmans et al50 Yes Yes Yes Yes No No No Yes No No Yes 6/10
Fimland et al41 Yes Yes No Yes No No No No No Yes Yes 4/10
Non-RCT Sabapathy et al39 Yes Yes No Yes No No No Yes No Yes Yes 5/10
De Bolt et al51 Yes Yes No Yes No No No Yes No Yes Yes 6/10
PEDro¼Physiotherapy Evidence Database scale, RCT¼ randomized controlled trial.
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TABLE 2. Overview of Trials of Strength Training Interventions in Individuals With Parkinson Disease or Multiple Sclerosis
Reference
Experimental/
Control (n)
Stage of
Disease
Mean Age
(SD)
Experimental
Intervention
Control/Comparison
Intervention
Measures/
Results
Parkinson disease
RCT
Paul et al47 Exp¼ 20 Hoehn and Yahr Exp¼ 68.1 5.6 Lower body re/machine Sham low-intensity exercises
trunk/lower body
Power "
Con¼ 20 Con¼ 64.5 7.4 (noncontinuous) Strength "
Movement speed "
Falls !
Balance !
Mobility !
Functional capacity !
PRET-PD RCT (Corcos
et al44 and Prodoehl
et al46)
Exp¼ 24 Hoehn and Yahr Exp¼ 59.0 4.6 Full body RE/ machine and
free weights
Modified fitness counts UPDRS-III "
mFC¼ 24 I–V mFC¼ 58.6 5.6 (noncontinuous) Strength "
Quality of life !
Balance "
Mobility "
Functional capacity !
Shulman et al13 Exp¼ 28 Hoehn and Yahr Exp¼ 65.3 11.3 Lower body RE/ machine Low-intensity treadmill Mobility "
LIT¼ 26 I–III LIT¼ 65.8 11.5 (noncontinuous) High-intensity treadmill Strength "
HIT¼ 26 HIT¼ 66.1 9.7 UPDRS-III (motor) "
Falls !
Fatigue !
Quality of life !
Mood !
Sage et al48 Exp¼ 18 NR Exp¼ 68.7 8.3 Whole-body work out Daily living activities
Con¼ 18 Con¼ 68.6 8.1 (noncontinuous) UPDRS-III "
Aerobic¼ 17 Aerobic¼ 65.8 9-9
Aquatic¼ 12 Aquatic¼ 63.1 9.2
SAFEx¼ 24 SAFE¼ 68.0 11
Bloomer et al49 Exp¼ 8 Hoehn and Yahr Exp¼ 61.0 2.0 Lower body RE/machine Standard care Oxidative and antioxidant
markers "
Con¼ 8 I and II Con¼ 57.0 3.0 (noncontinuous)
Non-RCT
Hass et al40 Exp¼ 9 Hoehn and Yahr Exp¼ 67 8.0 Lower body and core/
Machine and theraband
Standard care Mobility "
Con¼ 9 I–III Con¼ 64 7.0 (noncontinuous) Strength "
Schilling et al14 Exp¼ 9 Hoehn and Yahr Exp¼ 61.3 8.6 Lower body/machine (non-
continuous)
Standard care Strength "
Con¼ 9 I and II/III Con¼ 57.0 7.1 Functional capacity !
Mobility "
Balance !
Dibble et al42,43 Exp¼ 10 Hoehn and Yahr Exp¼ 64.3 9.6 Eccentric resistance training
ergometer
Standard care Strength "
Con¼ 9 I–III Con¼ 67.0 10.2 (continuous) Quadriceps muscle volume
"
UPDRS-III (motor) !
Quality of life "
Mobility "
Functional capacity (TUG) "
(stair descent) " 
Multiple sclerosis
RCT
Medina-Perez et al45 Exp¼ 30 EDSS: 1.0–6.0 Exp¼ 49.6 11.0 Lower body/machine Standard care Strength "
Con¼ 12 Con¼ 46.2 7.5 (noncontinuous) Power "
Muscle Endurance !
Dalgas et al16–19 Exp¼ 19 EDSS: 3.0–5.5 Exp¼ 49.1 8.4 Lower body/machine Standard care EMG activity "
Con¼ 19 DC: RR Con¼ 47.7 10.4 (noncontinuous) Strength "
Thigh volume "
Fatigue "
Mood "
Quality of life (physical) "
CSA II/IIa muscle fibers "
Functional capacity "
Dodd et al15 Exp¼ 39 AID: 2,3 or 4 Exp¼ 47.7 10.8 Lower body/machine Standard care Strength "
Con¼ 37 DC: RR Con¼ 50.4 9.6 (noncontinuous) Muscle endurance "
Fatigue "
quality of life (physical
domain) "
Mobility !
Broekmans et al50 Exp¼ 11 EDSS: 2.0–6.5 Exp¼ 4.5 1.3 Lower body/machine Normal living habits Strength "
ExpþES¼ 11 ExpþES¼ 4.4 0.9 (noncontinuous) Mobility !
Con¼ 14 Con¼ 4.1 1.1 Balance "
Fimland et al41 Exp¼ 7 EDSS: 2.0–6.5 Exp¼ 53.0 4.0 Lower body/machine Standard care Strength "
Con¼ 7 DC: NR Con¼ 54.0 2.0 (noncontinuous) EMG activity"
Motor output "
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Paul et al47 did not report significant changes in mobility after
strength training. In contrast, Prodoehl et al46 and Shulman
et al13 found significant improvements in mobility as a result
of strength training. The 3 nonrandomized controlled
trials12,39,41,42 that reported on mobility as an outcome also
documented improvements.
Balance
Two randomized46,47 and 2 nonrandomized controlled
trials14,39 examined the effect of strength training on balance
outcomes in Parkinson disease. Balance was evaluated across
trials using a variety of outcomes including the single leg stance,
choice stepping task, berg balance scale, functional reach test, 5
time sit to stand test, and the activities-specific balance confi-
dence scale. Paul et al47 did not find a significant improvement
in balance as a result of strength training. Prodoehl et al46 by
contrast reported a significant improvement in balance after
strength training. Both nonrandomized controlled trials14,39
were unable to find a significant improvement in balance after
strength training.
Functional Capacity
One randomized trial44 examined the effect of strength
training on functional capacity. Corcos et al44 assessed func-
tional capacity using the modified Physical Performance Test
and reported no significant changes after strength training in the
intervention or control group.
Quality of Life
Two randomized13,44 and 1 nonrandomized controlled
trial42 evaluated the effect of strength training on quality of
life. All 3 trials assessed quality of life using the 39-Item
Parkinson Disease Questionnaire. Both randomized controlled
trials10,11 did not report a significant improvement in quality of
life after strength training. Dibble et al42 by contrast reported a
significant improvement in quality of life in the intervention
group after strength training.
Oxidative and Antioxidant Markers
One randomized controlled trial49 in Parkinson disease
measured changes in blood oxidant and antioxidant marker
levels and reported significant increases in antioxidant marker
levels (superoxide dismutase [9.9%] and glutathione peroxidase
[1.8%]) and a significant reduction in oxidative stress marker
levels (malondialdehyde [15%] and hydrogen peroxide [16%]).
Mood
One randomized controlled trial13 evaluated the effect of
strength training on mood in Parkinson disease. Shulman et al13
found no significant changes in mood after strength training
using the Beck Depression Inventory.
Fatigue
One randomized controlled trial13 evaluated the effect of
strength training on fatigue in Parkinson disease. Shulman
et al13 used the 16-item Parkinson Fatigue Scale and found
no significant change in fatigue after strength training in the
strength training intervention group or high- and low-intensity
treadmill intervention groups.
Falls
Two randomized controlled trials11,45 evaluated the effect
of strength training on falls in people with Parkinson dis-
ease.13,47 Falls were assessed using the New Freezing of Gait
Questionnaire47 and Falls Efficacy Scale.13 No trial reported a
significant effect on falls outcomes after strength training.
Skeletal Muscle Volume
One nonrandomized controlled trial43 evaluated the effect
of strength training on quadriceps muscle volume in Parkinson
disease. Dibble et al43 found a significant increase in quadriceps
muscle volume using magnetic resonance imaging after
strength training in the intervention group only.
Multiple Sclerosis
Functional Mobility
Two randomized15,50 and 2 nonrandomized controlled
trials39,51 evaluated the effect of strength training on functional
mobility in multiple sclerosis. Functional mobility was assessed
across trials using the 2 minute walk test, 10 meter walk test,
timed 25 foot walk and timed up and go. No trial reported a
Reference
Experimental/
Control (n)
Stage of
Disease
Mean Age
(SD)
Experimental
Intervention
Control/Comparison
Intervention
Measures/
Results
Non-RCT
Sabapathy et al39 Exp¼ 15 DSS: 1–3 Exp¼ 55.0 7.0 Upper and lower body and
core
Endurance Exercise Balance !
END¼ 6 DC: RR, SP, PP (noncontinuous) Mobility !
Strength !
Mood !
quality of life !
Fatigue !
MSIS physical!
MSIS psychological !
DeBolt et al51 Exp¼ 19 EDSS: 2.0–6.0 Exp¼ 51.6 7.2 Weighted vest Standard care Leg extensor power "
Con¼ 17 Con¼ 47.8 10.5 Home-based resistance train-
ing
Functional capacity !
(noncontinuous) Balance !
"¼ significant improvement, !¼ no significant change, #¼ significant deterioration, " ¼ time effect, AID¼ ambulation index score, Con¼ control group, CSA¼ cross sectional area,
DC¼ disease course, DSS¼ disease steps scale, EDSS¼ expanded disability status scale, EMG¼ electromyography, END¼ endurance training, ES¼ electro-stimulation, Exp¼ experimental group,
MSIS¼multiple sclerosis impact scale, P¼Primary progressive, RCT¼ randomized controlled trial, RE¼ resistance exercise, RR¼ relapse remitting, SAFE¼ sensory attention focused-exercise,
SP¼ secondary progressive, TUG¼ timed up and go, UPDRS-III¼Unified Parkinson Disease Rating Scale Version-III.
TABLE 2. (Continued )
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significant improvement in mobility as a result of strength
training.
Balance
One randomized50 and 2 nonrandomized39,51 controlled
trials evaluated the effect of strength training on balance in
multiple sclerosis. Balance was evaluated across trials using the
Functional Reach Test,39,50 Four Square Step Test,39 and
AccuswayPLUS force platform.51 Broekmans et al50 reported
a significant improvement in balance in the intervention group
only as a result of strength training. However, Sabapathy et al39
and DeBolt et al51 did not find significant improvements in
balance after strength training.
Functional Capacity
One randomized controlled trial16 evaluated the effect of
strength training on functional capacity outcomes in multiple
sclerosis. Dalgas et al16 reported a significant improvement in
functional capacity (computed as 1/4 [chair stand test post/chair
stand test pre]þ [stair climb test post/stair climb test pre]þ [10
meter walk test post /10 meter walk test pre]þ [6 minute walk test
post / 6 minute walk test pre] 100) as a result of strength training.
Quality of Life
Two randomized15,17 and 1 nonrandomized controlled
trial39 reported on quality of life outcomes after strength
training in multiple sclerosis. Quality of life was assessed across
trials using the Short Form-3617,39 and the World Health
Organisation Quality of Life-BREF.15 Dodd et al15 and Dalgas
et al17 reported a significant improvement in quality of life in
the intervention group as a result of strength training. In
contrast, Sabapathy et al39 found no significant improvement
in quality of life after strength training.
Electromyography Activity
Two randomized controlled trials17,40 assessed the effect
of strength training on electromyography activity during maxi-
mum voluntary isometric contractions. Dalgas et al recorded
surface electromyography signals from the Vastus Lateralis,
Rectus Femoris, and Semitendinosus during maximal voluntary
isometric contractions of the knee flexors and extensors
(assessed at 708 knee flexion), using bipolar electrodes. The
upper electrode of each pair was placed at the midpoint between
the Spina Iliaca anterior superior and patellar basis. After
12 weeks of strength training, Dalgas et al found significant
improvements in maximal isometric (mV) knee extension and
knee flexion activity (semitendinosus: 27.6%; vastus lateralis:
27%; rectus femoris: 28%) in the intervention group, but not the
control group. Fimland et al41 recorded surface electromyo-
graphy activity during maximum voluntary isometric contrac-
tions of the plantar flexors (ankle positioned at 908), using
bipolar surface electrodes placed according to Surface
TABLE 4. Summary of Retention, Adherence and Adverse Events in Parkinson Disease orMultiple Sclerosis Strength Training Trials
Trial Reference Participant Retention Dropouts Participant Adherence Adverse Events
Parkinson disease
RCT
Paul et al47 RE: 18/20 (90%) RE: 2/20 (10%) RE: 84.1% RE: pelvic fracture (UTI), low back pain
CG: 18/20 (90%) CG: 2/20 (10%) CG: 94.1% CG: exacerbated hernias (UTI)
PRET-PD RCT (Corcos et al44
and Prodoehl et al46)
RE: 19/24 (79.2%) RE: 5/24 (20.8%) NR RE: 1 (wrist pain)
CG: 16/24 (66.6%) CG: 8/24 (33.3%) CG: 1 (back surgery)
Shulman et al13 RE: 22/28 (78.5%) RE: 6/28 (11.5%) NR No serious adverse events
CG: 22/26 (84.6%) CG: 4/26 (15.4%)
CG: 23/26 (88.4%) CG: 3/26 (11.6%)
Sage et al48 RE 18/18 (100%) RE: 0/10 (0%) NR No adverse events
CG: 18/18 (100%) CG: 0/10 (0%)
Bloomer et al49 RE: 6/8 (75%) RE: 2/8 (25%) NR NR
CG: 7/8 (87.5%) CG: 1/8 (12.5%)
Non-RCT
Hass et al40 RE: 9/9 (100%) RE: 0/9 (0%) NR No adverse events
CG: 9/9 (100%) CG: 0/9 (0%)
Schilling et al14 RE: 8/9 (88.8%) RE: 1/9 (11.2%) NR NR
CG: 7/9 (77.7%) CG: 2/9 (22.3%)
Dibble et al42,43 RE: 10/10 (100%) RE: 0/10 (0%) NR NR
CG: 9/10 (90%) CG: 1/10 (10%)
Multiple sclerosis
RCT
Medina-Perez et al45 RE: 30/30 (100%) RE: 0/30 (0%) RE: 95.4% No adverse events
CG: 12/12 (100%) CG: 0/12 (0%) CG: NR
Dalgas et al16–19 RE: 15/19 (78.9%) RE: 4/9 (21.1%) NR RE: 1 (lower back pain)
CG: 16/19 (84.2%) CG: 3/19 (15.8%)
Dodd et al15 RE: 36/39 (92.3%) RE: 3/39 (7.7%) RE: 92% No adverse events
CG: 31/37 (83.7%) CG: 6/37 (16.3%) CG: 62%
Broekmans et al50 EXP: 11/11 (100%) EXP: 0/11 (0%) 99% all groups Severe relapse
EXPþES: 10/11 (90%) EXPþES: 1/11 (9%) Perceived lack of time to continue
CON: 12/14 (86%) CON: 2/14 (14%) Mild stroke (unrelated)
Fimland et al41 RE: 7/7 (100%) RE: 0/7 (0%) NR No adverse events
CG: 7/7 (100%) CG: 0/7 (0%)
Non-RCT
Sabapathy et al39 RE: 11/14 (73.3%) RE: 3/14 (26.6%) NR No adverse events
CG: 5/6 (83.3%) CG: 1/6 (16.7%)
DeBolt et al51 RE: 19/20 (95%) RE: 1/20 (5%) 95% NR
CG: 17/17 (100%) CG: 0/17 (0%)
CG¼ comparison group, NR¼ not reported, RCT¼ randomized controlled trial, RE¼ resistance exercise.
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Electromyography for the Noninvasive Assessment of Muscles
recommendations. Fimland et al41 reported significant improve-
ments (15%) in surface electromyography activity of the plantar
flexors after 3 weeks of strength training in the intervention
group in comparison to the control group.
Skeletal Muscle Volume and Architecture
Only 1 randomized controlled trial18 measured changes to
thigh volume, muscle fiber numbers, type, and size. Muscle
biopsies of the vastus lateralis (middle portion) were taken to
assess changes in muscle fiber number, type, and size. Dalgas
et al18 reported a significant increase in the cross sectional area
of type II and IIa vastus lateralis muscle fibers after strength
training in the intervention group only.
Fatigue
Two randomized15,17 and 1 nonrandomized controlled
trial39 evaluated the effect of strength training on fatigue in
multiple sclerosis. Fatigue was assessed across trials using a
variety of outcomes including the Modified Fatigue Scale and
Fatigue Severity Scale, Multidimensional Fatigue Inventory.
Dodd et al15 reported a significant improvement in the level of
fatigue experienced (24%) after 10 weeks of twice weekly
strength training. Similar findings were reported by Dalgas
et al,17 who reported a 10% improvement in the level of fatigue
experienced after strength training. Sabapathy et al39 also
reported a significant improvement in the level of fatigue
experienced as a result of strength training.
Mood
One randomized17 and 1 nonrandomized controlled trial39
examined the effect of strength training on mood outcomes in
multiple sclerosis. Dalgas et al17 reported significant improve-
ments (2.4 points) in mood using the Major Depression
Inventory as a result of strength training. In contrast, Sabapathy
et al39 found no significant changes in mood using the Beck
Depression Inventory after strength training.
Muscle Endurance
Two randomized controlled trials15,45 evaluated the effect
of strength training on muscle endurance in multiple sclerosis.
Medina-Perez et al45 measured muscle endurance as the maxi-
mum number of repetitions that a participant could perform
during a single set of knee extension using a load of 40% of the
maximum voluntary isometric contraction, whereas Dodd
et al15 measured endurance by counting the number of repeti-
tions that a participant could complete on the seated leg press
and reverse leg press using a load of 50% of 1RM. Medina-
Perez et al45 did not find a significant change in muscle
endurance in the intervention or control group after strength
training. In contrast, Dodd et al15 reported a significant
improvement in muscle endurance in the intervention group
relative to the control group after strength training.
DISCUSSION
This review found that strength training is useful for
improving muscle strength in Parkinson disease and to a lesser
extent multiple sclerosis. Evidence also showed that strength
training is helpful for improving clinical measures of disease
progression and mobility in Parkinson disease. However, the
evidence is unclear regarding the efficacy of strength training
on falls, quality of life, fatigue, functional capacity, and balance
in Parkinson disease. In multiple sclerosis, strength training was
also found to improve fatigue, quality of life, muscle power,
electromyography activity, and functional capacity. However,
its effect on balance and mood remains equivocal.
An increase in strength was the most consistently reported
benefit of strength training in people with Parkinson disease and
multiple sclerosis. A meta-analysis of the extracted strength
data revealed that strength training had a larger effect on
strength in people with Parkinson disease (d¼ 0.87) than
multiple sclerosis (d¼ 0.33) (Figure 2). Different pathological
mechanisms underpinning impairments in strength in each
disease are likely to account for this discrepancy. For instance,
impairments in strength in multiple sclerosis are thought to be
mediated by central52,53 (spinal and supraspinal mechanisms)
and muscular deficits,54–56 whereas in Parkinson disease
impairments in strength are thought to result from central
deficits only.57–59 This finding suggests that strength training
may only produce meaningful benefits in strength in people
with Parkinson disease.
Strength training trials in Parkinson disease also reported
improvements in mobility. The improvements were reported on
short and longer duration mobility assessments, suggesting that
strength training has a favorable effect on multiple aspects of
mobility. This finding is consistent with the supposition that
muscle strength strongly predicts mobility in people with
Parkinson disease.60,61 Surprisingly, no improvements in mobi-
lity were reported in individuals with multiple sclerosis after
strength training. This finding was unexpected, as the strength
training interventions in Parkinson disease and multiple
sclerosis trials, for the most part, used similar training frequen-
cies (2–3 times per week), resistance exercises (leg press, knee
extension, knee flexion, and calf raises), and sets per exercise
(2–3). This may indicate that strength training is not capable of
improving mobility in individuals with multiple sclerosis. The
inability to improve mobility may be explained by the smaller
improvements in strength observed in individuals with multiple
sclerosis. Indeed, recent findings show that muscle strength
significantly predicts performance on mobility tasks in individ-
uals with multiple sclerosis.62 Alternatively, it is possible that
the strength training interventions used in the multiple sclerosis
trials were unable to provide a stimulus sufficient to improve
mobility in multiple sclerosis, and perhaps more intense or
specific training interventions may be required.
In addition, strength training was found to have a positive
effect on disease progression in people with Parkinson disease
(Unified Parkinson Disease Rating Scale-Version 3). Interest-
ingly, improvements in disease progression were observed in a
cohort with mild-to-advanced disability that were not on medi-
cation, suggesting that strength training alone may be capable of
positively impacting on disease progression in individuals at all
stages of Parkinson disease. The positive effect of strength
training on disease progression may have been mediated by
favorable central changes. For instance, recent evidence shows
that repetitive force generation increases neuronal activation in
the basal ganglia, thalamus, parietal cortex, cerebellum, and
motor cortex.63–66 Furthermore, emerging evidence has shown
that exercise interventions can increase regional brain volume
and structural connectivity in patients with Parkinson disease
and other neurodegenerative disorders.67–70 Further studies are
required to confirm the latter remarks.
In multiple sclerosis trials, improvements in strength were
accompanied by significant improvements in fatigue, quality of
life, muscle power, maximal electromyography activity, and
functional capacity. The reported improvements in fatigue are
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of clinical interest given that 33%–75% of individuals with
multiple sclerosis suffer from fatigue.71–73 Nevertheless, this
finding was not surprising, given that exercise has previously
been reported to improve fatigue in multiple sclerosis.74 The
improvements in fatigue may in part explain the benefits
observed in quality of life, especially considering that fatigue
is an important predictor of quality of life in people with
multiple sclerosis.75,76 The increases in muscle power and
maximal electromyography activity are consistent with the
observed improvements in strength. The reported improve-
ments in lower limb strength, fatigue, and muscle power likely
contributed to the improvement in functional capacity docu-
mented by Dalgas et al.16 Indeed, recent findings have shown
that strength,77 fatigue,78 and muscle power61 significantly
influences functional capacity in individuals with multiple
sclerosis and other neurodegenerative disorders.
It is important to note that most trials included in this
systematic review recruited individuals with mild-to-moderate
disability. The higher level of disability in individuals at
advanced stages of Parkinson disease or multiple sclerosis
may have led researchers to only include individuals at
early-to-middle stages of both diseases. The same level of
benefits after strength training may not be possible in individ-
uals at more advanced stages of Parkinson disease or multiple
sclerosis. Future trials assessing the effect of strength training in
individuals with Parkinson disease and multiple sclerosis with a
severe level of disability are therefore warranted.
In general, the trials displayed adequate methodological
quality, with PEDro scores ranging from 4 to 8 in both diseases.
The major methodological shortcomings found using the
PEDro scale included a failure to report concealed allocation
(criteria 3), participant blinding (criteria 5), therapist blinding
(criteria 6), and outcome assessor blinding (criteria 7). It is
important to acknowledge that it is often not possible to blind
participants or therapists to exercise or group allocation.79 Trial
scores generated using the PEDro scale may therefore under-
estimate the quality of evidence.
In addition to evaluating trials using the PEDro scale, we
also performed a critical appraisal of specific intervention
characteristics important to strength training trials. This apprai-
sal found that specific intervention characteristics were typi-
cally well detailed, with the exception of the level of
supervision and strength training intensity. The lack of data
reported on the level of supervision and the intensity of strength
training performed is of concern in particular, as a high level of
supervision as well as an appropriate intensity of strength
training is required to maximize therapeutic benefits and avoid
potential injury.80 The poor level of reporting on strength
training progression in multiple sclerosis trials is also concern-
ing, given that modulating the progression of strength training
is important to avoid injury and training plateaus.81 The
inadequate reporting of participant adherence in both disease
populations was also worrisome, as it does not enable internal
and external examination of what dose of strength training is
Parkinson’s disease
Corcos et al 2013 (elbow flexion)
Schilling et al 2010 (leg press)
Hass et al 2012 (knee extension)
Hass et al 2012 (knee flexion)
Paul et al 2014 (knee flexors)
Paul et al 2014 (hip flexors)
Paul et al 2014 (hip abductors)
Shulman et al 2013 (leg press)
Shulman et al 2013 (leg extension)
Paul et al 2014 (leg extensors)
Dibble et al 2009 (knee extension/less affected)
Dibble et al 2009 (knee extension/more affected)
Subtotal (I-squared = 46.1%, p = 0.040)
Subtotal (I-squared = 0.0%, p = 0.914)
multiple sclerosis
Dodd et al 2011 (leg press)
Dodd et al 2011 (reverse leg press)
Fimland et al 2010 (plantar flexion)
Sabapathy et al 2010 (grip strength)
Dalgas et al 2009, 2010, 2013 (knee extension)
Dalgas et al 2009, 2010, 2013 (knee flexion)
Dalgas et al 2009 (leg press)
Broekmans et al 2011 (knee extension 45)
Broekmans et al 2011 (knee flexion 45)
Medina-Perez et al 2014 (knee extension)
Heterogeneity between groups: p = 0.000
Overall (I-squared = 48.9%, p = 0.005)
ES (95% CI)
0.55
0.54
1.41
1.23
1.87
1.62
0.48
0.65
0.39
0.43
0.92
0.79
0.88
(–0.08, 1.19)
(–0.43, 1.52)
(0.42, 2.41)
(0.26, 2.20)
(1.16, 2.59)
(0.94, 2.31)
(–0.40, 1.36)
(–0.23, 1.53)
(–0.24, 1.02)
(–0.20, 1.06)
(–0.25, 1.59)
(–0.20, 0.73)
(–0.23, 0.69)
(–0.73, 1.24)
(–0.91, 1.09)
(–0.11, 0.57)
(–0.01, 0.68)
(–0.02, 1.40)
(–0.02, 1.74)
(–0.22, 1.50)
(–0.32, 0.70)
(0.15, 0.48)
(0.39, 0.66)
(0.14, 1.44)
(0.66, 1.09)
0.26
0.23
0.26
0.09
0.23
0.34
0.69
0.86
0.64
0.19
0.31
0.52
Study
ID
0
0.
31
0.
52
0.
87
FIGURE 2. Meta-analysis of trials that measured muscle strength.
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required to maximize therapeutic benefits and avoid injury in
such populations.
Based on our findings and American College of Sports
Medicine guidelines, we recommend that individuals with
multiple sclerosis or Parkinson disease perform progressive
submaximal strength training (whole-body single and multi-
joint resistance exercises) on at least 2 nonconsecutive days per
week for an hour under direct supervision (eg, physiotherapist,
exercise physiologist, strength and conditioning specialist) to
improve muscle strength and other disease specific clinical
features (Parkinson disease: mobility and disease progression;
multiple sclerosis: fatigue, quality of life, muscle power,
maximal electromyography activity, and functional capacity).
Limitations
Lack of consistent reporting and heterogeneity of study
outcomes between trials made it difficult to draw firm con-
clusions beyond improvements in muscle strength with respect
to the benefits of strength training for individuals with multiple
sclerosis or Parkinson disease.
CONCLUSION
Trials investigating the effect of strength training in indi-
viduals with Parkinson disease or multiple sclerosis are in their
infancy. Nevertheless, benefits in strength were found after
strength training in individuals with Parkinson disease and, to a
lesser extent, in multiple sclerosis. Some evidence was also
found to suggest that strength training has a positive effect on
clinical disease progression and mobility in individuals with
Parkinson disease. Similarly, some evidence showed that
strength training is beneficial for muscle power, maximum
electromyography activity, fatigue, functional capacity, and
quality of life in individuals with multiple sclerosis. Additional
trials employing high-quality methodological designs are
required to confirm and expand on these findings. Such trials
may provide evidence-based rationale for using strength train-
ing as a therapy for other neurodegenerative disorders such as
Alzheimer disease and Huntington disease.
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